title: International perceptions and approval of gene therapy.
abstract: Gene therapy is in clinical trials in a number of countries, raising the question of whether different ethical standards can be justified in different countries. One key issue is how divergent are the perceptions and bioethical reasoning of peoples around the world. An International Bioethics Survey with 150 questions, including 35 open ones, was developed to look at how people think about diseases, life, nature, and selected issues of science and technology, biotechnology, genetic engineering, genetic screening, and gene therapy. The mail response survey was conducted in 1993 among the public in Australia, India, Israel, Japan, New Zealand, Russia, and Thailand, and the same written survey was conducted among university students in Australia, Hong Kong, India, Japan, New Zealand, The Philippines, Russia, Singapore, and Thailand. Similar questions were included in an international high school education bioethics survey among high school teachers in Australia, Japan, and New Zealand. Further international comparisons to the United States and Europe are made. About three-quarters of all samples supported personal use of gene therapy, with higher support for children's use of gene therapy. The diversity of views was generally similar within each country. The major reasons given were to save life and increase the quality of life. About 5-7% rejected gene therapy, considering it to be playing God, or unnatural. There was very little concern about eugenics (0.5-2%), and more respondents gave supportive reasons like "improving genes," especially in Thailand and India. Support for specific applications was significantly less for "improving physical characters," "improving intelligence," or "making people more ethical" than for curing diseases like cancer or diabetes, but there was little difference between inheritable or noninheritable gene therapy.
authors.affiliation: Institute of Biological Sciences, University of Tsukuba, Ibaraki, Japan.
authors.forename: D R
authors.initials: DR
authors.lastname: Macer
authors.forename: S
authors.initials: S
authors.lastname: Akiyama
authors.forename: A T
authors.initials: AT
authors.lastname: Alora
authors.forename: Y
authors.initials: Y
authors.lastname: Asada
authors.forename: J
authors.initials: J
authors.lastname: Azariah
authors.forename: H
authors.initials: H
authors.lastname: Azariah
authors.forename: M V
authors.initials: MV
authors.lastname: Boost
authors.forename: P
authors.initials: P
authors.lastname: Chatwachirawong
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: V
authors.initials: V
authors.lastname: Kaushik
mesh_terms: D026688:Bioethical Issues; D017690:Cell Transplantation; D002648:Child; D003466:Cultural Characteristics; D018864:Cultural Diversity; D028781:Ethical Relativism; D004992:Ethics, Medical; D030342:Genetic Diseases, Inborn; D024861:Genetic Enhancement; D015316:Genetic Therapy; D005854:Germ Cells; D017408:Guidelines as Topic; D006266:Health Education; D006801:Humans; D038622:Internationality; D011639:Public Opinion; D018570:Risk Assessment; D012926:Social Control, Formal